Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study

BACKGROUND: The long-term continuation of the low-dose antithyroid drug (ATD) beyond the standard duration of ATD therapy of 12–18 months to prevent recurrent hyperthyroidism (RH) is recommended with low quality of evidence. OBJECTIVES: To examine whether long-term continuation of low-dose ATD beyon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lertwattanarak, Raweewan, Kunavisarut, Tada, Sriussadaporn, Sutin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578883/
https://www.ncbi.nlm.nih.gov/pubmed/36267362
http://dx.doi.org/10.1155/2022/1705740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578883/
https://www.ncbi.nlm.nih.gov/pubmed/36267362
http://dx.doi.org/10.1155/2022/1705740

Ejemplares similares